DADC
FPRX

D.A. Davidson & Co’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

D.A. Davidson & Co’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-622
Closed -$18K – 2155
2017
Q2 		$18K Hold
622
– – ﹤0.01% 1854
2017
Q1 		$22K Sell
622
-1,149
-65% -$50.6K ﹤0.01% 1813
2016
Q4 		$88K Sell
1,771
-792
-31% -$41.6K ﹤0.01% 1354
2016
Q3 		$133K Sell
2,563
-640
-20% -$30.6K ﹤0.01% 1126
2016
Q2 		$131K Buy
+3,203
New +$139K ﹤0.01% 1021

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

D.A. Davidson & Co's FPRX Position: Q3 2017 in Review

D.A. Davidson & Co sold out of Five Prime Therapeutics, Inc. (FPRX) in Q3 2017, closing a stake of 622 shares — an estimated $18K sold.

D.A. Davidson & Co first reported a position in FPRX in Q2 2016 and held it in 5 quarters. The position peaked at $133K in Q3 2016. 126 funds tracked by Wall St. Rank hold FPRX as of Q3 2017.

  • D.A. Davidson & Co reported no remaining Five Prime Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • D.A. Davidson & Co sold 622 Five Prime Therapeutics, Inc. shares in Q3 2017, an estimated $18K.
  • D.A. Davidson & Co first reported a position in Five Prime Therapeutics, Inc. in Q2 2016 and held it in 5 quarters.
  • D.A. Davidson & Co's Five Prime Therapeutics, Inc. position peaked at $133K in Q3 2016.
  • 126 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2017.

Based on D.A. Davidson & Co's 13F filing for Q3 2017, filed 8 Nov 2017.